* If you want to update the article please login/register
Purpose of Investigation Based on high local control success and an outstanding safety profile, recommendations are recommended that thermal ablation be used to eliminate small unresectable colorectal liver metastases. This systematic review and meta-analysis compare the safety and effectiveness of local ablative therapies for unresectable intermediate-size CRLM. Our Research Highlights We searched for journals that reported the treatment results of unresectable intermediate-size CRLM treated with thermal ablation, irreversible electroporation, or stereotactic ablative body-radiotherapy in an organized manner. Per-patient local control ranged 22–90% for all procedures; 22–89% for thermal ablation, 44 percent for IRE, and 67–90% for SABR, depending on radiation dose; and 44–90% for SABR. Even for smaller CRLM, cold ablative therapy is safe and can result in long-term disease prevention. While SABR and tumuor-bracketing methods such as IRE are expected to be less prone to size, the available evidence backs any assertions of superiority over another is unsubstantiated by the available evidence.
Source link: https://doi.org/10.1007/s11912-022-01248-6
Background Research in the treatment of non-small cell lung cancer has yielded promising results with stereotactic ablative radiotherapy of oligometastatic disease, wherein distant disease can be restricted to one or a few distant organs by host factors. In up to 20% of NSCLC patients who were initially considered to be surgical candidates, mediastinal examination has now identified occult nodal disease. If the rate of treatment change is greater than 10% in the first stage, 10 patients with oligometastatic NSCLC with up to 5 synchronous metastases will be admitted to the second stage. An additional 19 patients will be enrolled in the second stage if the rate of treatment change is greater than 10% in the first stage. Patients will be assessed by EBUS or a mixed modality EBUS/EUS-B to evaluate bilateral lymph node stations from the N3 to N1 transition.
Source link: https://doi.org/10.1186/s12885-022-09563-8
We have found 38 cases of patients with immature red hypertrophic scar from surgery or injury, which are all younger than six months old. The Vancouver Scar Scale score was used to analyze the scar changes; all the patients were followed for 3 more months after the last therapy. Following the therapies, the combined VSS score after the treatment was 0. 96 1. 53, which in comparison to previous treatment VSS scores 8. 86 1. 43, showed a significant decline. The combination of a 1565-nm non-ablative laser and a small dose of local compound betamethasone can effectively eliminate the early red hypertrophic scar, which has no adverse side effects; it will give our physicians a new weapon in fighting those difficult-to-manage early scar formations.
Source link: https://doi.org/10.1007/s10103-022-03564-6
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions